Traxoprodil

Research use only, not for human use.

A potent and NR2B-selective NMDA receptor antagonist; potently protects cultured hippocampal neurons from glutamate toxicity (IC50=10 nM).

A potent and NR2B-selective NMDA receptor antagonist; potently protects cultured hippocampal neurons from glutamate toxicity (IC50=10 nM); shows neuroprotective, analgesic, and anti-Parkinsonian effects in animal studies.Parkinson's Disease Phase 2 Discontinued(In Vivo):Traxoprodil is potent at blocking haloperidol-induced catalepsy and with an ED50 less than 1 mg/kg. Traxoprodil is effective at 1 mg/kg to block NMDA (ip) stimulated cfos induction in mice. Traxoprodil at a dose of 20 and 40 mg/kg exhibits antidepressant activity in the Forced swim test and it is not related to changes in animals’ locomotor activity. Traxoprodil (20 nM i.c.v.) increases the latency to generalized tonic-clonic seizures induced by PTZ (70 mg/kg; i.p.). Traxoprodil (60 mg/kg, p.o.) increases the latency to clonic and generalized seizures, and decreases the total time spent in seizures.

——

——

CP-101606 | CP101606

Membrane Transporter/Ion Channel

iGluR

iGluR

Neurological Disease

Depression

134234-12-1

327.424

C20H25NO3

>98% (HPLC)

DMSO : ≥ 150 mg/mL 458.13 mM

CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O

1-((1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)-4-phenylpiperidin-4-ol

(-20℃)

With Ice Pack

≥ 2 years